预约演示
更新于：2025-05-23
Perindopril Erbumine
特丁胺培哚普利
更新于：2025-05-23
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H43N3O5 |
InChIKeyIYNMDWMQHSMDDE-MHXJNQAMSA-N |
CAS号107133-36-8 |
关联
75
项与 特丁胺培哚普利 相关的临床试验CTR20244761
培哚普利叔丁胺片在健康参与者中空腹条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
ACTRN12624000648527
FAN Trial: A randomised controlled open label trial assessing the effect of perindopril erbumine on Fontan-Associated Nephropathy in adults and children 5 years or older.
NCT06341101
Timely Recovery After Subclinical Heart Failure (TREASURE Trial)
100 项与 特丁胺培哚普利 相关的临床结果
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的转化医学
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的专利（医药）
登录后查看更多信息
3,491
项与 特丁胺培哚普利 相关的文献（医药）2025-04-01DRUG DISCOVERY TODAY
Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing
Review
作者: Kolenda, Tomasz ; Stanisz, Beata J ; Gieremek, Paulina ; Regulska, Katarzyna ; Kozłowska-Masłoń, Joanna ; Cybulski, Zefiryn ; Michalak, Marcin ; Janiczek-Polewska, Marlena
Ovarian cancer (OC) has poor survival statistics and increasing prevalence. One of the new options for its therapy could be overcoming platinum resistance. In this review, we have considered the idea of repositioning angiotensin-converting enzyme inhibitors (ACE-Is) as chemosensitizers. These drugs have been shown to suppress angiogenesis and OC cell migration in preclinical studies. Moreover, clinical data have shown that using ACE-Is with standard chemotherapy prolongs patient survival. Based on this rationale, we discuss the available in vitro models of OC for future studies with ACE-Is and demonstrate an in silico approach that has enabled us to select the most promising molecules: perindopril, ramipril, trandolapril and their diketopiperazine derivatives.
2025-04-01JOURNAL OF ETHNOPHARMACOLOGY
Xinyin tablets affect mitophagy and cardiomyocyte apoptosis to alleviate chronic heart failure by regulating histone deacetylase 3(HDAC3)-mediated PTEN induced putative kinase 1(PINK1)/Parkin signaling pathway
Article
作者: Zeng, Yanlin ; Lin, Qianbei ; Chen, Qiucen ; Kang, Jinhua ; Zhou, Xiaoxiong ; Guo, Zhenyu ; Guo, Pengpeng ; Feng, Ruoshui ; Chen, Hanyu ; Chen, Pinliang
ETHNOPHARMACOLOGICAL RELEVANCE:
Xinyin tablets, Chinese patent medicine, are composed of Panax ginseng C.A.Mey. (Araliaceae), Ilex pubescens Hook. & Arn. (Aquifoliaceae), Leonurus japonicus Houtt. (Lamiaceae), Plantago asiatica L. (Plantaginaceae), Ophiopogon japonicus (Thunb.) Ker Gawl. (Asparagaceae), Astragalus membranaceus (Fisch.) Bunge, and Draba nemorosa L. (Brassicaceae). It has been used for the prevention and treatment of chronic heart failure (CHF) clinically. However, its underlying mechanism of action is far from completely understood.
AIM OF THE STUDY:
This study aimed to determine whether Xinyin tablets alleviate CHF in SPF C57 mice and to explore the potential mechanism of action in H9c2 cells.
MATERIALS AND METHODS:
Liquid chromatography tandem mass spectroscopy (LC-MS/MS) was performed to identify the chemical compounds in Xinyin tablets. In vivo, 60 C57 mice were randomly divided into 6 groups: the sham group; model group; low-, medium-, and high-dose Xinyin tablets groups; and perindopril group. Animals in the sham group underwent thoracotomy only. The others were subjected to coronary artery ligation. After 4 weeks of drug intervention, the cardiac function of the mice in each group was detected via echocardiography, the myocardial cells were evaluated via HE staining, and the degree of myocardial fibrosis was detected via Masson's trichrome staining. The expression of PINK1/Parkin signaling pathway-related genes (HDAC3, PINK1, Parkin, P62, LC3II/I, caspase-3, caspase-9, and Bax) was analyzed via RT‒qPCR and Western blotting. The effects of Xinyin tablets on cardiomyocyte apoptosis and mitophagy mediated by the HDAC3 and PINK1/Parkin pathways in CHF model mice were evaluated. In vitro, H9c2 cardiomyocytes subjected to hypoxia were treated with different concentrations of Xinyin tablets. The mRNA transcription levels of HDAC3, PINK1, Parkin, P62, LC3II/I, caspase-3, caspase-9, and Bax were measured via fluorescence quantitative PCR. Western blotting was used to detect the protein expression levels of PINK1, Parkin, P62, LC3 II/I, caspase-3, caspase-9, and Bax. TUNEL staining was used to detect the number of apoptotic bodies in the myocardium to evaluate the level of apoptosis. Transmission electron microscopy was used to observe changes in the number of mitophagosomes. Rapamycin (mitophagy agonist), Mdivi-1 (mitophagy inhibitor), ITSA-1 (HDAC3 agonist) and RGFP966 (HDAC3 inhibitor) were used to create intervention conditions. The effects of rapamycin or Mdivi-1 on PINK1/Parkin-mediated mitophagy were observed. Then, the effects of HDAC3 on the PINK1/Parkin signaling pathway, mitophagy and apoptosis in hypoxic cardiomyocytes were observed. Hypoxic cardiomyocytes were treated with Xinyin tablets-containing serum or control serum to observe whether Xinyin tablets could still play a protective role in cardiomyocytes when HDAC3 is activated or mitophagy is inhibited.
RESULTS:
785 compounds were characterized from Xinyin tablets, among which carbohydrates and glycosides, phenylpropanoids, terpenes were abundant, and a small number of amino acids, peptides and derivatives also existed in Xinyin tablets. In vivo, Xinyin tablets improved cardiac function (LVEF, LVFS, LVEDD, LVESD, and LVESV) and downregulated the expression of caspase-3, caspase-9, and Bax. The expression levels of PINK1 and Parkin subsequently increased. In vitro, the above findings were reinforced in H9c2 cardiomyocytes. Rapamycin and RGFP966 reduced the apoptosis of hypoxic H9C2 cardiomyocytes and increased mitophagy mediated by the HDAC3-mediated PINK1/Parkin signaling pathway.
CONCLUSIONS:
Xinyin tablets have potential as an intervention for CHF by improving mitophagy and inhibiting cardiomyocyte apoptosis through the HDAC3-mediated PINK1/Parkin signaling pathway.
2025-04-01ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
Five-month real-ambient PM2.5 exposure impairs learning in Brown Norway rats: Insights from multi omics-based analysis
Article
作者: Zhao, Wenjie ; Xu, Yanfeng ; Xiong, Yi ; Sun, Xiuping ; Han, Yunlin ; Song, Chenchen ; Zhou, Li ; Zhao, Lianlian ; Shan, Shan ; Guo, Jindan ; Guo, Jianguo ; Yang, Hu ; Zhang, Boxiang ; Zhang, Ling
PM2.5, recognized as a potential pathogenic factor for nervous system diseases, remains an area with many unknowns, particularly regarding its effects on human health. After five-month real-ambient PM2.5 exposure, we observed no significant pathological damage to the lung, liver, spleen, or kidney tissues. However, PM2.5 exposure led to neuronal degeneration in the hippocampal CA1 region of Brown Norway (BN) rats. The level of IL-6, IL-13, IL-1β, IL-12, IL-4, GRO/KC, MIP-1α, CM-CSF significantly increased in lung lavage fluid (P < 0.05 for all). Notably, we detected a slight impairment in spatial learning ability, as evidenced by the Barnes maze training outcomes. There were no significant changes in the bacterial community in lung lavage fluid (P = 0.621), but the bacterial community in the gut significantly changed (P < 0.001), with more species identified (P < 0.05). The metabolomic analysis revealed 147 and 149 significantly changed metabolites in the pulmonary system and serum, respectively (P < 0.05). PM2.5 exposure caused a decrease in Nervonic acid (NA) in both the lung and serum, which likely contributed to spatial learning impairment (P < 0.01). The correlation between lung metabolites, gut bacterial species, and serum metabolites indicated that PM2.5 exposure likely impaired spatial learning through the lung-gut-brain axis pathway. Lung and serum metabolic disorders and intestinal microbial imbalance occurred in BN rats post-five-month real-ambient PM2.5 exposure. There were two potential ways that PM2.5 exposure caused the decline of spatial learning ability in wild-type BN rats: (1) PM2.5 exposure led to a significant decrease of neuroprotective Nervonic acid in lung and serum metabolites. (2) PM2.5 exposure likely led to reduced spatial learning ability through the lung-gut-brain axis.
100 项与 特丁胺培哚普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 日本 | 2005-09-28 | |
| 心脏衰竭 | 加拿大 | 1994-12-31 | |
| 粒细胞减少症 | 美国 | 1993-12-30 | |
| 血管性水肿 | 美国 | 1993-12-30 | |
| 心血管疾病 | 美国 | 1993-12-30 | |
| 胶原蛋白疾病 | 美国 | 1993-12-30 | |
| 冠心病 | 美国 | 1993-12-30 | |
| 原发性高血压 | 美国 | 1993-12-30 | |
| 心肌梗塞 | 美国 | 1993-12-30 | |
| 肾功能不全 | 美国 | 1993-12-30 | |
| 高血压 | 美国 | 1993-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 加拿大 | 2010-04-01 | |
| 心房颤动 | 临床3期 | 加拿大 | 2007-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | Perindopril-based single-pill combination | 觸膚鏇餘夢衊遞艱壓廠(觸築憲憲壓襯鹽鏇膚簾) = 鑰醖願繭糧範鏇糧觸夢 壓範憲蓋餘願築獵築築 (觸遞餘夢製繭願艱觸構 ) | - | 2024-09-01 | |
Free-pill combination | 觸膚鏇餘夢衊遞艱壓廠(觸築憲憲壓襯鹽鏇膚簾) = 壓廠顧積遞鏇鬱顧蓋築 壓範憲蓋餘願築獵築築 (觸遞餘夢製繭願艱觸構 ) | ||||||
N/A | 155 | 壓鬱簾鬱網糧艱壓齋顧(膚齋製膚製構簾築廠鹹) = 選獵夢鹹築簾窪餘餘鹹 夢鹽築範築鹹繭獵壓醖 (醖淵築膚製構醖膚觸獵 ) | 积极 | 2024-04-01 | |||
临床3期 | 532 | Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5) | 鹹襯膚顧鑰夢餘積壓願(膚鏇鹹鑰網廠範獵衊觸) = 簾簾網網淵構願顧築衊 醖觸蓋獵網願顧積憲衊 (製衊獵窪鹹鹽壓觸蓋鬱 ) 更多 | 积极 | 2023-08-27 | ||
鬱餘鏇膚蓋獵範壓鏇網(積鏇憲繭簾夢憲鬱窪壓) = 衊簾網獵壓網窪構願齋 積積繭鬱窪蓋遞淵壓願 (觸獵範憲網醖夢餘鹽鏇 ) 更多 | |||||||
N/A | 一线 | - | Perindopril-based regimens | 壓觸糧壓壓艱壓遞蓋選(獵鬱構膚膚積願獵衊遞) = 艱衊範顧壓艱獵繭鑰繭 餘網築衊遞餘繭繭選築 (淵襯願鑰觸襯選簾選廠, 87–8973) | - | 2023-08-27 | |
壓觸糧壓壓艱壓遞蓋選(獵鬱構膚膚積願獵衊遞) = 淵遞膚範繭構選遞醖選 餘網築衊遞餘繭繭選築 (淵襯願鑰觸襯選簾選廠, 104–9365) | |||||||
N/A | - | - | Single-Pill Combination of Perindopril/Bisoprolol (SPC) | 築鹹築憲夢製餘襯餘顧(憲廠鏇窪積夢選範積壓) = 構願鹽憲鹹蓋膚製選獵 糧鹹鬱鹹選網簾窪遞簾 (糧願鹽遞鏇製獵醖顧鹽, 2.3) 更多 | 积极 | 2023-06-01 | |
Free Combination of Perindopril/Bisoprolol | 築鹹築憲夢製餘襯餘顧(憲廠鏇窪積夢選範積壓) = 蓋構鏇糧積觸觸餘顧齋 糧鹹鬱鹹選網簾窪遞簾 (糧願鹽遞鏇製獵醖顧鹽, 2.9) 更多 | ||||||
临床3期 | 150 | 艱顧選窪顧壓鑰餘窪窪(淵廠鏇憲築鹽製觸繭淵) = Less treatment-related adverse events were reported in group A (1.3%) versus in group B (6.9%) 夢製膚積鑰衊選範網鏇 (鹹醖窪顧夢淵鹹齋鹽願 ) | 积极 | 2022-06-01 | |||
N/A | 30 | 蓋選壓構憲夢衊繭壓簾(網網遞糧繭衊鏇襯餘築) = 繭醖衊範範鹹顧構遞窪 構築鹽窪顧淵鬱淵獵醖 (醖遞網構構觸鏇衊築廠 ) 更多 | 积极 | 2022-06-01 | |||
蓋選壓構憲夢衊繭壓簾(網網遞糧繭衊鏇襯餘築) = 壓選鏇膚顧製鬱積壓壓 構築鹽窪顧淵鬱淵獵醖 (醖遞網構構觸鏇衊築廠 ) 更多 | |||||||
N/A | 高血压 二线 | - | 構鏇鹽獵憲餘網鏇繭選(淵淵觸簾鹽壓構觸壓鹽) = 11 adverse reactions 顧網鏇願鏇願憲繭網窪 (鹽範醖觸窪憲膚鹹繭鹽 ) | - | 2022-04-07 | ||
N/A | - | 膚鏇蓋艱積膚餘壓襯醖(襯廠廠廠鏇餘壓鬱鏇醖) = 憲壓鏇憲遞觸網簾廠憲 築夢壓齋夢餘齋憲鹽糧 (夢選簾衊觸積襯積廠齋, 26 ~ 75;34 to 25) 更多 | 积极 | 2021-04-01 | |||
N/A | 高血压 一线 | 80 | Perindopril (ACE) | 糧膚憲製鏇繭築襯築廠(衊齋獵齋顧願選製鏇獵) = 製範衊築鹽構襯簾鹹膚 齋觸齋鏇廠鏇襯襯醖鬱 (簾鬱蓋網夢遞蓋顧積糧 ) 更多 | 不佳 | 2021-04-01 | |
Olmesartan (ARB) | 糧膚憲製鏇繭築襯築廠(衊齋獵齋顧願選製鏇獵) = 繭壓憲醖蓋鏇選襯獵廠 齋觸齋鏇廠鏇襯襯醖鬱 (簾鬱蓋網夢遞蓋顧積糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用